Betaini announced that its wholly-owned subsidiary, Shanghai Betaini Health Technology Co., Ltd., received a medical device registration certificate from the National Medical Products Administration on September 10, 2026. The product is an injectable sodium hyaluronate solution for superficial dermal injection in the face, temporarily improving adult skin dryness and dull complexion. The company stated that this product further supplements its medical device product line in the skin health field, enriches its product matrix, and helps enhance core competitiveness.
Yunnan Botanee Bio-Technology Group Co LtdWholly-owned subsidiary received medical device registration for injectable sodium hyaluronate solution, expanding its skin health product line.
